J B Pharma eyes US, Europe generics mart

 The company has already provided exclusive marketing rights of its ciprofloxacin to Larnett Company Inc, to market the drug in the United States, and is in the process of looking at propspective partners in Europe.

 Although JBCPL has not fixed up revenues it aims to generate out of the deals with US and European partners, the worldwide generics market is worth 80 billion US dollars.

 Executive director (production) Kamlesh Udani said even if a few billion dollars were the share of JBPCL, this will be considered satisfactory.